CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
BI 730357 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03804671
NCT03804671Phase 1Completed
CompareCT.gov

Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 730357 Administered as an Oral Dose With an Intravenous Microtracer Dose of BI 730357 BS (C-14) in Healthy Male Volunteers

Boehringer Ingelheim·interventional·Posted Jan 15, 2019·Updated Jul 25, 2023

In Brief

A Phase 1 clinical trial evaluating BI 730357 and BI 730357 mixed with [C-14] BI 730357 BS for Healthy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

To investigate the absolute oral bioavailability of BI 730357 administered as tablet compared with \[C-14\]BI 730357 BS administered as intravenous microtracer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNetherlands
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJan 15, 2019
Enrollment StartJan 31, 2019
Primary CompletionMar 26, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.5 years ago

Interventions

BI 730357drug

Oral dose

BI 730357 mixed with [C-14] BI 730357 BSdrug

Intravenous dose